CART123

CART123 is a chimeric antigen receptor T-cell therapy designed to target CD123, a protein highly expressed on acute myeloid leukemia (AML) cells and leukemic stem cells. This immunotherapy involves engineering a patient's own T cells (autologous) or donor T cells (allogeneic) to express a receptor that recognizes CD123, enabling them to identify and kill CD123-positive cancer cells. The therapy has shown potent anti-leukemic activity in preclinical studies but faces challenges in clinical settings, including cytokine release syndrome (CRS) and potential impact on normal hematopoiesis due to CD123 expression on normal hematopoietic cells.

Other names

CD123 chimeric antigen receptor T cellsCD-123 chimeric antigen receptor T cellsCD 123 chimeric antigen receptor T cellsanti-CD123 CAR T cellsanti-CD-123 CAR T cellsanti-CD 123 CAR T cells